The small heat shock protein HSPB1 is a multifunctional, α-crystallin-based protein that has been shown to be neuroprotective in animal models of motor neuron disease and peripheral nerve injury. Missense mutations in HSPB1 result in axonal Charcot-Marie-Tooth disease with minimal sensory involvement (CMT2F) and distal hereditary motor neuropathy type 2 (dHMN-II). These disorders are characterized by a selective loss of motor axons in peripheral nerve resulting in distal muscle weakness and often severe disability. To investigate the pathogenic mechanisms of HSPB1 mutations in motor neurons in vivo, we have developed and characterized transgenic PrP-HSPB1 and PrP-HSPB1(R136W) mice. These mice express the human HSPB1 protein throughout the nervous system including in axons of peripheral nerve. Although both mouse strains lacked obvious motor deficits, the PrP-HSPB1(R136W) mice developed an age-dependent motor axonopathy. Mutant mice showed axonal pathology in spinal cord and peripheral nerve with evidence of impaired neurofilament cytoskeleton, associated with organelle accumulation. Accompanying these findings, increases in the number of Schmidt-Lanterman incisures, as evidence of impaired axon-Schwann cell interactions, were present. These observations suggest that overexpression of HSPB1(R136W) in neurons is sufficient to cause pathological and electrophysiological changes in mice that are seen in patients with hereditary motor neuropathy.
Introduction
Distal hereditary motor neuropathy (dHMN) is clinically similar to axonal forms of Charcot-Marie-Tooth disease (CMT2) but lacks significant clinical or electrophysiological evidence of sensory axon involvement (Pareyson and Marchesi, 2009; Reilly and Shy, 2009) . Missense mutations in HSPB1 (also known as heat shock 27 kDa protein 1, HSP27) result in CMT disease type 2F (CMT2F; OMIM 606595) and dHMN type II (OMIM 608634) (Benedetti et al., 2010; Chung et al., 2008; Dimos et al., 2008; Evgrafov et al., 2004; Houlden et al., 2008; Ikeda et al., 2009; James et al., 2008; Luigetti et al., 2010; Solla et al., 2010) . HSPB1 mutations usually result in an adult onset motor neuropathy, however early-onset phenotypes of childhood have also been reported (Dierick et al., 2008; Kijima et al., 2005) .
Motor neuropathies due to HSPB1 mutations usually present with slowly progressive peroneal muscular atrophy and have electrophysiological evidence of decreased compound muscle action potentials (CMAPs) with normal or slightly reduced sensory nerve action potentials (SNAPs). Few pathological reports from human nerve biopsy exist, however morphological analysis of a sural nerve biopsy from a patient with an HSPB1p.S135C mutation revealed evidence of myelin remodeling with excessively thick myelin and fissures in the setting of normal density of myelinated fibers (Benedetti et al., 2010) . Ultrastructural analysis revealed atrophic axons with increased microtubule density (Benedetti et al., 2010) . In a patient with an HSPB1p.T180I mutation, sural nerve biopsy showed mildly reduced myelinated fiber density (Luigetti et al., 2010) .
To study the physiological role of HSPB1 in motor neurons and to investigate the pathogenic mechanisms of mutations in HSPB1, we have developed transgenic PrP-HSPB1 and PrP-HSPB1(R136W) mice. The PrP-HSPB1(R136W) mice did not develop a motor phenotype despite high levels of expression in neurons. These mice did develop electrophysiological and pathological evidence of an axonal motor neuropathy that was age-dependent. Neurobiology of Disease 47 (2012) [163] [164] [165] [166] [167] [168] [169] [170] [171] [172] [173] 
